Table 1.
Patient characteristics
| Variable | Prophylaxis patients (N = 47) | Treatment patients (N = 48) |
|---|---|---|
| Age (years), median (IQR) | 55 (40–62) | 61 (49.0–66.8) |
| Male, n (%) | 28 (60) | 28 (58) |
| Weight (kg), median (IQR) | 71.3 (60.5–80.9) | 74 (62.5–87.7) |
| Height (cm), median (IQR) | 175 (167–182) | 174 (169.3–180.8) |
| BMI (kg/m2), median (IQR) | 23.1 (20.6–25.9) | 23.7 (21.4–27.8) |
| Transplant type | ||
| HSCT | 31 | |
| allogeneic stem cell transplant | 29 | |
| autologous stem cell transplant | 2 | |
| SOT | 47 | 17 |
| kidney | 6 | 10 |
| lung | 19 | 1 |
| liver | 8 | 5 |
| heart | 7 | 1 |
| small intestine | 3 | |
| multiple solid organs | 4 | |
| Treatment | ||
| SOT | ||
| primary CMV infection, therapy | 12 | |
| CMV reactivation, therapy | 5 | |
| HSCT | ||
| CMV pre-emptive therapy | 11 | |
| HHV-6 reactivation, therapy | 17 | |
| CMV pre-emptive therapy and HHV-6 therapy in the same time period | 3 | |
| Therapy duration in study (days), median (IQR) | 18 (5–37) | 14 (10–33) |
| Route of administration | ||
| PO | 24 | 14 |
| IV | 10 | 17 |
| IV and PO | 13 | 17 |